基石藥業-B(02616.HK):抗PD-L1抗體在rr-ENKTL患者中呈現良好試驗數據 完全緩解率達31.8%
格隆匯11月7日丨基石藥業-B(02616.HK)宣佈,2019年美國血液學會(“ASH”)年會已正式接受CS1001-201臨牀研究摘要(摘要編號:2833),並且摘要內容已於昨日在會議的官方網站上線上發佈。此外,公司還將在會議上以海報展示形式發佈CS1001-201研究的進一步更新試驗數據。基石藥業首席醫學官楊建新博士表示:“ENKTL的發生與EBV感染導致的PD-L1表達提高存在緊密關聯,這預示着阻斷PD-1/PD-L1通路將很有可能為ENKTL患者提供有效的治療。ASH已公佈的摘要顯示,CS1001的客觀緩解率達40.9%,完全緩解率達31.8%且緩解可持續,並且在安全性方面也有良好的表現。這些數據對於rr-ENKTL的治療是個不小的突破,也都將支持CS1001在rr-ENKTL治療領域的進一步開發。我們期待在ASH2019年年會上以海報展示形式分享更多令人振奮的更新數據。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.